ABVC BioPharma, Inc. (ABVC)
NASDAQ: ABVC · Real-Time Price · USD
2.980
+0.010 (0.34%)
Aug 14, 2025, 11:30 AM - Market open
ABVC BioPharma Employees
As of December 31, 2024, ABVC BioPharma had 19 total employees, including 16 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
19
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$20,592
Profits / Employee
-$218,691
Market Cap
48.43M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 19 | 0 | - |
Dec 31, 2023 | 19 | -4 | -17.39% |
Dec 31, 2022 | 23 | -7 | -23.33% |
Dec 31, 2021 | 30 | -4 | -11.76% |
Dec 31, 2020 | 34 | -4 | -10.53% |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ABVC News
- 8 months ago - ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners - GlobeNewsWire
- 10 months ago - ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners - GlobeNewsWire
- 1 year ago - ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements - GlobeNewsWire
- 1 year ago - AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share - GlobeNewsWire
- 1 year ago - ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M - GlobeNewsWire
- 1 year ago - ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M - GlobeNewsWire
- 1 year ago - ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M - GlobeNewsWire
- 1 year ago - ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine - GlobeNewsWire